NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
AlsNewsFebruaryMajorDane'sResearchElectionCandidateCampaignPartyStrikesDigestSundayTimelinePrivateCrisisPoliticalEricBlueCreditFundingRamadanAdditionalLaunches
AlsNewsFebruaryMajorDane'sResearchElectionCandidateCampaignPartyStrikesDigestSundayTimelinePrivateCrisisPoliticalEricBlueCreditFundingRamadanAdditionalLaunches
All Articles
STAT+: Hims to buy Eucalyptus as it looks to expand globally
STAT News
Published 3 days ago

STAT+: Hims to buy Eucalyptus as it looks to expand globally

STAT News · Feb 19, 2026 · Collected from RSS

Summary

Hims & Hers is buying the Australian telehealth firm Eucalyptus as it looks to make inroads in more countries globally.

Full Article

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71.LONDON — The telehelath platform Hims & Hers is looking to expand internationally, announcing Thursday that it was buying the Australian digital health company Eucalyptus. Hims framed the deal, which includes a $240 million upfront cash payment, as one that would allow it to make further inroads in the U.K., Germany, and Canada and move into Australia and Japan. The total value of the acquisition could reach $1.15 billion if the pact hits certain financial targets over the next several years. The deal is expected to close in the middle of the year. Hims, which in the U.S. offers patients everything from compounded obesity drugs to, as of this month, a cancer screening test, said buying Eucalyptus would expand its personalized offerings to more customers globally. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe


Share this story

Read Original at STAT News

Related Articles

STAT News1 day ago
STAT+: Nature Medicine to investigate study that found cancer treatment is better in morning

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning.

STAT News1 day ago
STAT+: DOJ, Ohio attorney general accuse OhioHealth of driving up prices, crowding out competition

Regulators say Ohio hospital system made it difficult for health insurers to offer cheaper plans.

STAT News2 days ago
STAT+: Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

STAT News2 days ago
STAT+: Element Biosciences launches table-top sequencer capable of $100 genome

And other biotech news brought to you by The Readout newsletter

STAT News2 days ago
STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV

STAT News2 days ago
ACIP meeting postponed, for reasons that are unclear

And other health news from today's Morning Rounds newsletter